AC
DMIIR

Aristeia Capital’s Drugs Made In America Acquisition II Corp Right DMIIR Stock Holding History

Aristeia Capital’s Portfolio DMIIR Stock Details DMIIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108K Hold
1,350,000
– – ﹤0.01% 611
2026
Q1 		$108K Buy
1,350,000
+250,000
+23% +$28.4K ﹤0.01% 516
2025
Q4 		$154K Buy
+1,100,000
New +$157K ﹤0.01% 437

Other funds holding DMIIR

MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Aristeia Capital's DMIIR Position: Q2 2026 in Review

Aristeia Capital held its Drugs Made In America Acquisition II Corp Right (DMIIR) position steady in Q2 2026 at 1,350,000 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #611.

Aristeia Capital first reported a position in DMIIR in Q4 2025 and has held it in 3 quarters since. The position peaked at $154K in Q4 2025. 62 funds tracked by Wall St. Rank hold DMIIR as of Q2 2026.

  • Aristeia Capital held 1,350,000 shares of Drugs Made In America Acquisition II Corp Right worth $108K as of Q2 2026.
  • Aristeia Capital left its Drugs Made In America Acquisition II Corp Right share count unchanged in Q2 2026.
  • Drugs Made In America Acquisition II Corp Right made up ﹤0.01% of Aristeia Capital's portfolio in Q2 2026, its #611 holding.
  • Aristeia Capital first reported a position in Drugs Made In America Acquisition II Corp Right in Q4 2025 and has held it in 3 quarters since.
  • Aristeia Capital's Drugs Made In America Acquisition II Corp Right position peaked at $154K in Q4 2025.
  • 62 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp Right as of Q2 2026.

Based on Aristeia Capital's 13F filing for Q2 2026, filed 14 Aug 2026.